ArticleBrain and behavior2025
Genetic Insights Into the Link Between Restless Legs Syndrome and Diabetic Nephropathy Risk.
Article in Brain and behavior, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRestless legs syndrome (RLS) is a common neuro-sensory disorder associated with various metabolic diseases, including diabetes mellitus and its complications. Observational studies suggest a potential association between RLS and diabetic complications; however, the causal relationship remains unclear due to confounding factors and reverse causation. This study aims to assess the causal relationship between RLS and diabetes, including its complications, using a bidirectional Mendelian randomization (MR) approach.
methodsGenetic instruments derived from the latest genome-wide association study (GWAS) data for RLS, Type 1 diabetes, Type 2 diabetes, and diabetic complications (diabetic nephropathy, diabetic retinopathy, and diabetic neuropathy) were selected on the basis of MR assumptions. For causal inference, RLS was used as the exposure, whereas diabetes and its complications were considered outcomes. Reverse MR analyses were performed to assess potential causal effects of diabetes and its complications on RLS. Primary analysis used the inverse-variance weighted (IVW) method, with IVW radial and robust adjusted profile score (RAPS) as supplementary methods. Heterogeneity, pleiotropy, and robustness were assessed in both discovery (UK Biobank) and validation (FinnGen) datasets.
resultsForward MR analysis revealed a significant causal effect of RLS on the risk of diabetic nephropathy in both the discovery (IVW: OR = 1.049, p = 0.0238) and validation cohorts (IVW: OR = 1.067, p = 0.0028). However, no significant causal relationships were found for other primary outcomes, including Type 2 diabetes (IVW: OR = 1.011, 95% CI: 0.994-1.029) and Type 1 diabetes (IVW: OR = 0.995, 95% CI: 0.967-1.023). Sensitivity analyses showed no evidence of heterogeneity or horizontal pleiotropy. Reverse MR analysis did not demonstrate a causal effect of diabetes or its complications on RLS.
conclusionsThe findings suggest that RLS causally increases the risk of diabetic nephropathy. Early recognition and management of RLS in patients with diabetes may help prevent or delay the progression of nephropathy. Further studies are warranted to explore underlying mechanisms and potential clinical interventions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.